Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Fingolimod |
Synonyms | |
Therapy Description |
Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fingolimod | Gilenya | FTY720 | PP2A Activator 7 | Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Indication other than cancer | not applicable | Fingolimod | FDA approved | Actionable | Gilenya (fingolimod) is FDA approved for use in patients with relapsing forms of multiple sclerosis (FDA.gov). | detail... detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02490930 | Phase I | Fingolimod | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | Completed | USA | 0 |